The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors

Hazem Ghebeh, Shamayel Mohammed, Abeer Al-Omair, Amal Qattan, Cynthia Lehe, Ghofran Al-Qudaihi, Naser Elkum, Mohamed Alshabanah, Suad Bin Amer, Asma Tulbah, Dahish Ajarim, Taher Al-Tweigeri, Said Dermime Dermime

Research output: Contribution to journalArticle

373 Citations (Scopus)

Abstract

B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immuno-genicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.

Original languageEnglish
Pages (from-to)190-198
Number of pages9
JournalNeoplasia
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2006
Externally publishedYes

Fingerprint

Ductal Carcinoma
Breast Neoplasms
T-Lymphocytes
B7 Antigens
Neoplasms
Tumor-Infiltrating Lymphocytes
Progesterone Receptors
Estrogen Receptors
Lung Neoplasms
Epithelium
Immunohistochemistry
Monoclonal Antibodies
Lymphocytes
Apoptosis
Mortality

Keywords

  • B7-H1
  • Breast cancer
  • PD-L1
  • Prognostic factors
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research

Cite this

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma : Correlation with important high-risk prognostic factors. / Ghebeh, Hazem; Mohammed, Shamayel; Al-Omair, Abeer; Qattan, Amal; Lehe, Cynthia; Al-Qudaihi, Ghofran; Elkum, Naser; Alshabanah, Mohamed; Amer, Suad Bin; Tulbah, Asma; Ajarim, Dahish; Al-Tweigeri, Taher; Dermime, Said Dermime.

In: Neoplasia, Vol. 8, No. 3, 03.2006, p. 190-198.

Research output: Contribution to journalArticle

Ghebeh, H, Mohammed, S, Al-Omair, A, Qattan, A, Lehe, C, Al-Qudaihi, G, Elkum, N, Alshabanah, M, Amer, SB, Tulbah, A, Ajarim, D, Al-Tweigeri, T & Dermime, SD 2006, 'The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors', Neoplasia, vol. 8, no. 3, pp. 190-198. https://doi.org/10.1593/neo.05733
Ghebeh, Hazem ; Mohammed, Shamayel ; Al-Omair, Abeer ; Qattan, Amal ; Lehe, Cynthia ; Al-Qudaihi, Ghofran ; Elkum, Naser ; Alshabanah, Mohamed ; Amer, Suad Bin ; Tulbah, Asma ; Ajarim, Dahish ; Al-Tweigeri, Taher ; Dermime, Said Dermime. / The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma : Correlation with important high-risk prognostic factors. In: Neoplasia. 2006 ; Vol. 8, No. 3. pp. 190-198.
@article{261fd695eb2340f8a21385347c9ce2d5,
title = "The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors",
abstract = "B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immuno-genicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34{\%} in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41{\%}). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.",
keywords = "B7-H1, Breast cancer, PD-L1, Prognostic factors, Tumor-infiltrating lymphocytes",
author = "Hazem Ghebeh and Shamayel Mohammed and Abeer Al-Omair and Amal Qattan and Cynthia Lehe and Ghofran Al-Qudaihi and Naser Elkum and Mohamed Alshabanah and Amer, {Suad Bin} and Asma Tulbah and Dahish Ajarim and Taher Al-Tweigeri and Dermime, {Said Dermime}",
year = "2006",
month = "3",
doi = "10.1593/neo.05733",
language = "English",
volume = "8",
pages = "190--198",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma

T2 - Correlation with important high-risk prognostic factors

AU - Ghebeh, Hazem

AU - Mohammed, Shamayel

AU - Al-Omair, Abeer

AU - Qattan, Amal

AU - Lehe, Cynthia

AU - Al-Qudaihi, Ghofran

AU - Elkum, Naser

AU - Alshabanah, Mohamed

AU - Amer, Suad Bin

AU - Tulbah, Asma

AU - Ajarim, Dahish

AU - Al-Tweigeri, Taher

AU - Dermime, Said Dermime

PY - 2006/3

Y1 - 2006/3

N2 - B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immuno-genicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.

AB - B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immuno-genicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.

KW - B7-H1

KW - Breast cancer

KW - PD-L1

KW - Prognostic factors

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=33646367200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646367200&partnerID=8YFLogxK

U2 - 10.1593/neo.05733

DO - 10.1593/neo.05733

M3 - Article

C2 - 16611412

AN - SCOPUS:33646367200

VL - 8

SP - 190

EP - 198

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 3

ER -